cyrilzakka/clinical-trials huggingface dataset:
Effectiveness of a Mobile Health Program in Pregnant Women

1. To evaluate the usability and user experience of the i-PregMom mobile application and digital dietary image recording among pregnant women.
2. To examine the effectiveness of digital mobile health interventions on blood glucose levels and gestational weight gain among pregnant women from 10-14 weeks to 24-28 weeks of gestation.

1. Sociodemographic variables: age, education level, marital status, occupation, and socioeconomic status.
2. Obstetric variables: gravidity, history of miscarriage, pregnancy complications, and mode of delivery.
3. Pre-pregnancy BMI.
4. Dietary habits, perceived healthy eating behaviors, and dietary patterns.
5. Psychological distress and depressive symptoms.
6. Gestational blood glucose levels and GWG

Eligibility Criteria:
Inclusion Criteria:

* Primiparous women aged ≥18 years.

Singleton pregnancy.

Pregnant women between 10 and 14 weeks of gestation, with gestational age calculated based on the first day of the last menstrual period.

Able to listen, speak, read, and write in Chinese.

Willing to provide prenatal weight and blood glucose data.

Possess a mobile communication device (such as a smartphone or social media account) and be able to receive emails.

Exclusion Criteria:

* Engaged in weight loss activities prior to pregnancy.

Diagnosed with chronic illnesses that may affect weight changes (e.g., psychiatric disorders, thyroid diseases).
Evaluation of the Optimal Technique for Determination of Renal Function of Critically Ill Patients

The purpose of this study is to evaluate the optimal technique for determination of the renal function of critically ill patients.


Eligibility Criteria:
Inclusion Criteria:

* Over 18 years old
* Intensive care patient
* Given informed consent
* Arterial infusion
* A bladder catheter

Exclusion Criteria:

* Diurese \< 400 mL/d
Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation

Age-related macular degeneration (AMD) is the chief cause of severe and irreversible loss of vision in developed countries. The prevalence of AMD increases dramatically with age.

The early stage (or dry AMD) is associated with minimal visual impairment and is characterized by large drusen and pigmentary abnormalities in the macula. The late stage is a neovascular, exudative form. This so called exudative AMD includes serous or hemorrhagic detachment of retinal pigment epithelium and choroidal neovascularization leading to severe loss of vision (20/200 or worse). Patients with unilateral CNV (choroidal neovascularisation) have a significant risk of CNV developing in the second eye.

Choroidal blood flow is of great importance for normal visual function. Several reports have provided evidence suggesting that choroidal blood flow is decreased in subjects with AMD. In late stages of AMD angiogenesis leads to the formation of choroidal neovascularization that can cause severe visual impairment by disrupting normal macular function.

The purpose of this evaluation is to investigate a possible link between alterations in choroidal blood flow and the development of CNV and serous detachment in the fellow eye of patients with AMD and unilateral neovascular maculopathy. This longitudinal study may provide important findings with respect to natural history and visual prognosis of patients with neovascularized AMD.

Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry


Eligibility Criteria:
Inclusion Criteria:

* Male or female patients with unilateral choroidal neovascular AMD and 2-4 risk factors for AMD in the fellow eye.
* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant Ametropy \< 4 dpt.

Exclusion Criteria:

* Abuse of alcoholic beverages
* Participation in a clinical trial in the 3 weeks preceding the study
* Any signs of diabetic retinopathy
* Glaucoma
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

The purpose of this research study is to see if subjects with Parkinson's disease who are experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary excessive movements) would benefit from a higher dose of Requip as compared to the maximum FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip as used in this study is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) at this dose level.


Eligibility Criteria:
Inclusion Criteria:

* Patients must give written informed consent prior to any specific study procedures.
* Males or females; females of childbearing age who are not currently pregnant must agree to use a medically accepted method of contraception throughout the study.
* Age greater than or equal to 25 years.
* Patients must be on a maximum dose of dopamine agonist drug (pergolide 4mg/day, pramipexole 4.5 mg/day or ropinirole 24mg/day).
* Stable dose of all medications for 4 weeks.

Exclusion Criteria:

* Current hallucinations.
* History of disabling hallucinations or hallucinations in past requiring treatment.
* Troublesome edema (swelling).
* Unstable depression.
* Female who is pregnant or lactating.
* Use of an investigational drug with in the last 30 days.
* Other inclusion or exclusion criteria to be evaluated by the physician.
Monovision vs Multifocal Lens Insertion in Cataract Patients

The investigators would like to assess whether monovision correction of multifocal lens insertion provides more satisfaction to cataract patients following an uncomplicated phacoemulsification surgery.


Eligibility Criteria:
Inclusion Criteria:

* Bilateral senile cataract

Exclusion Criteria:

* Glaucoma
* Corneal pathology
* Fundus pathology
* Severe neurological/mental diseases that interfere with visual acuity
* Former intraocular operation
The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)

The safety and efficacy of MK0724 will be assessed in patients with acute middle cerebral artery stroke using the Action Reach Arm Test (ARAT). This test allows measurement of a specific functional deficit and subsequent recovery correlating with the specific area of stroke in the brain.


Eligibility Criteria:
Inclusion Criteria:

* 18-80 yrs of age inclusive
* Patient is able to receive IV infusion 8-36 hours after stroke onset
* Baseline NIHSS of 6-18 inclusive

Exclusion Criteria:

* Patient had another stroke within 3 months preceding current stroke, patient's stroke is of origin other than MCA (e.g., non-ischemic, hemorrhage), significant cerebral edema, abnormal liver enzymes and abnormal renal and hepatic functions
Breathalyzer Validation Study

The proposed project will test three commercial cellphone breathalyzers against a police grade breathalyzer device.The study will test the accuracy of these smartphone breathalyzers at assessing Breath Alcohol Content (BrAC) against a standard police grade breathalyzer. This study aims to fill the knowledge gap by determining the validity of smartphone paired breathalyzer devices to accurately assess BrAC. Data collection includes collection of BrAC measurements, as well as survey data.


Eligibility Criteria:
Inclusion Criteria:

* Age 21-39 old
* Less than 4 drinking days and less than 12 drinks per week on average in the past 2 months
* Have previously consumed four (women) or five (men) or more standard drinks without problems
* A valid photo ID
* Willing to take public transportation home, via septa or an uber rideshare credit.

Exclusion Criteria:

* Desire alcohol treatment now or received it in the past 6 months
* Alcohol dependence with withdrawal per DSM-V criteria
* Non-English-speaking
* Individuals who have a medical condition or who are taking medication which limits or prevents the consumption of alcohol.
Trunk Stabilization Exercises Affect the Activity of the Upper Limb

The aim of the study was to analyze the effect of trunk stabilization exercises on coordinated movement of the affected upper limb in patients after stroke, using the Armoe®Spring device and the "wall" and "abacus" functional tests. The study group had physiotherapy based on the NDT Bobath concept and the control group used classic exercises.

Almost half of the stroke patients report impaired function of the upper limb and hand. Stability of the trunk is required for the proper movement of the body, including the legs and arms. The aim of the study was to analyze the effect of trunk stabilization exercises on coordinated movement of the affected upper limb in patients after stroke, using the Armoe®Spring device and the "wall" and "abacus" functional tests. Material and method: this is a randomized, double-blinded study. The research was carried out in the Rehabilitation Clinic on a group of 60 stroke patients who were randomly assigned to groups differing in the rehabilitation program. The study group had physiotherapy based on the NDT Bobath concept and the control group used classic exercises. The importance of the trunk for upper limb coordination was assessed on the Armeo®Spring device using three evaluation programs: "perpendicular hunting"; "horizontal hunting"; "reaction time" and two proprietary tests: "wall" and "abacus".

Eligibility Criteria:
Inclusion Criteria: 1) patients 5 to 7 weeks after ischemic stroke; 2) patients with hemiparesis after stroke; 3) subjects with poor trunk control; 4) subjects who were in a functional state allowing movements of the upper extremity; 5) muscle tension that allows movement; 6) no severe deficits in communication, memory, or understanding what can impede proper measurement performance;

Exclusion Criteria: 1) lack of possibility to adjust the orthosis to the patient's treated limb, 2) bone instability (non-fused fractures, advanced osteoporosis), 3) permanent contracture of the treated limb, 4) open skin lesions in the area of the treated upper limb, 5) sensory deficits, disturbances, 6) shoulder subluxation or pain 7) increased spasticity, 8) increased involuntary movements, e.g. ataxia, dyskinesia, myoclonic seizures, 9) unstable life functions: contraindications related to the respiratory system or the cardiovascular system (instability or the need to use supportive devices), 10) the need for long-term intravenous therapy, 11) postural instability, 12) contraindication to a sitting position, 13) confused or uncooperative patients, 14) severe cognitive impairment, 15) patients requiring isolation due to infections, 16) severe vision problems (the patient is not in the ability to observe the elements displayed on the computer screen), 17) epilepsy.
Feasibility of Monitoring Cancer Patients With a Smart T-shirt: Protocol for the OncoSmartShirt Study

The study will assess the feasibility of using the ChronolifeTM smart t-shirt for home monitoring of vital parameters in cancer patients during their treatment course. This study will bring new insights to how wearables and biometric data can be used as a part of symptom recognition in cancer patients during treatment course in the quest of increasing patients' quality of life.

Collecting biometric sensor data by wearables is an example of real-time patient-generated health data that can provide vital and detailed objective information about patients. This may have the potential to improve quality of oncological treatment and increase patients' quality of life.

Studies have shown that there may be a dissimilar perception on symptoms and side effects between patients and health care professionals. Wearables may help identifying symptoms earlier.

A new design of a wearable is a smart t-shirt. A smart t-shirt has sensors embedded in the fabric which generate measurement flows. This new tool provide more precise information without recall and reporting bias which may have the potential to lead to a better and more accurate cancer treatment.

Eligibility Criteria:
Inclusion Criteria:

* Danish cancer patients ≥18 years in antineoplastic treatment at Department of Oncology Rigshospitalet Denmark
* Both patients in curative and palliative care will be eligible
* 10 cancer patients under 39 years
* 10 cancer patients over 65 years
* Able to read and speak Danish

Exclusion Criteria:

* Serious cognitive deficits
Secondary Mentoring Program Evaluation

Mentorship is essential to job satisfaction and promotion among academic physicians, and literature suggests that a single mentor is rarely sufficient. The investigators are studying whether implementation of a secondary mentorship program among physicians at their institution leads to improved job satisfaction over 6 months.


Eligibility Criteria:
Inclusion Criteria:

Physician employed as full-time faculty in the Massachusetts General Hospital Department of Medicine.

Exclusion Criteria:

None
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

This study is intended to prospectively research the treatment reality and long-term disease control of Type 2 Diabetes Mellitus (T2DM) patients who are initiating 2nd line anti-diabetes treatment in sites across Japan.

This study is a single country, multicenter, observational, prospective, longitudinal cohort study which will include adult patients with documented history of T2DM who are initiating a second line oral or parenteral anti-diabetes mediation after their first line anti-diabetic therapy in real world setting. The follow-up period is 3 years. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician. Patients will not receive experimental intervention or experimental treatment as a consequence of their participation in the study.

Eligibility Criteria:
Inclusion Criteria:

1. Written consent obtained
2. Aged \> = 20 years
3. Diagnosed with type 2 diabetes mellitus
4. Initiating a second oral or parenteral anti-diabetic therapy added to oral anti-diabetic monotherapy or switching from the monotherapy to another monotherapy with different drug class

Exclusion Criteria:

1. Diagnosis of Type 1 Diabetes Mellitus
2. Current pregnancy
3. Current treatment for any cancer
4. Current dialysis treatment or renal transplantation
5. Current treatment with any oral steroids
6. Participation in any randomized control trials
7. Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker who does not understand the local language where interpreter are not available, psychiatric disturbances, alcohol or drug abuse).
Immersive Virtual Reality Techniques on the Effects on Cognition in People With Cancer

OncoBRAIN aims to assess the effect of an innovative immersive virtual reality-based (IVR) intervention that includes cognitive, physical activity and mindfulness exercises in people diagnosed with cancer and Chemotherapy-Related Cognitive Deficits (CRCD). The main objective of OncoBRAIN is to determine the benefits of RVI intervention on the cognitive, and emotional state and quality of life of people with cancer and CRQD. We hypothesize that in OncoBRAIN we will find improvements in people with cancer and CRCD who have received IVR stimulation compared to the control group with cancer and CRCD who have not received IVR stimulation. People in the experimental group will perform better than patients in the control group in cognition (episodic memory, executive function, attention, and information processing speed), show better emotional well-being and perceive a better quality of life at the end of the intervention.


Eligibility Criteria:
Inclusion Criteria:

A. Over 18 years of age and under 65 years of age B. Diagnosis of cancer C. At least 4 weeks since the last chemotherapy treatment session D. Presence of cognitive complaints after chemotherapy treatment E. Level of primary education to be able to perform the cognitive tests. F. Consent to participate in the study

Exclusion Criteria:

A. Established diagnosis prior to cancer diagnosis of psychiatric, neurological, neurodevelopmental or systemic disorder causing cognitive deficits.

B. Motor or sensory impairments that preclude completion of the program. C. Undergoing chemotherapy treatment
Prospective Evaluation of Effectiveness and Safety of Closed-Loop Spinal Cord Stimulation in Treating Patients With Chronic Pelvic Pain

Spinal cord stimulation (SCS) is an effective treatment for patients with chronic pelvic pain. The investigators will evaluate how safe and effective closed-loop spinal cord stimulation is in treating these patients; closed-loop spinal cord stimulation is a more novel method in delivering spinal cord stimulation that controls energy output of the device based on real-time feedback on how the device is stimulating the spinal cord.


Eligibility Criteria:
Inclusion Criteria:

The investigators will include all adult patients (18 or older) with pelvic pain more than 6 months that has not responded to conservative medical management

Exclusion Criteria:

* Major untreated medical comorbidities (uncontrolled diabetes mellitus, severe obesity, uncontrolled cardiopulmonary disease, etc.)
* Secondary causes of pelvic pain that can be treated with appropriate medical or surgical interventions
* Major untreated psychological comorbidities
* Anatomical challeneges to place spinal cord stimulator
* Ongoing legal or disability claims
The Acute Effect of Cervical Mobilization in Parkinson's Disease

Patients with Idiopathic Parkinson's disease have balance and gait problems due to sensory and motor impairments. In the literature, there are lots of studies including various approaches for rehabilitation of these parameters such as sensory interventions, conservative treatments, neurophysiological approaches and motor imagery. However, taking into account of literature, there is no study investigating the effects on balance and gait of cervical mobilization by stimulating proprioceptors and vestibular receptors. Therefore, the aim of this study is to investigate the acute effect of cervical mobilization on balance and gait in patients with idiopathic Parkinson's disease.

Patients with Idiopathic Parkinson's disease have balance and gait problems due to sensory and motor impairments. In the literature, there are lots of studies including various approaches for rehabilitation of these parameters such as sensory interventions, conservative treatments, neurophysiological approaches and motor imagery. The posture of the cervical region is impaired by the findings of the disease such as rigidity, flexor posture and loss of axial rotation. Considering that the cervical region is rich in proprioceptors and one of the key points for the vestibular system, interventions to this area can be thought to contribute to postural control and gait. However, taking into account of literature, there is no study investigating the effects on balance and gait of cervical mobilization by stimulating proprioceptors and vestibular receptors. Therefore, the aim of this study is to investigate the acute effect of cervical mobilization on balance and gait in patients with idiopathic Parkinson's disease.

Eligibility Criteria:
Inclusion Criteria:

* Having been diagnosed with Idiopathic Parkinson's disease
* Being between the ages of 50-80
* Patients scoring \>24 on Standardized Mini Mental State Examination
* Modified Hoehn and Yahr stage 2-3
* No medication or dose changes during treatment
* Not participating in the physiotherapy and rehabilitation program in the last 6 months
* Volunteering to participate in the study

Exclusion Criteria:

* Vertebrobasilar insufficiency
* Other neurological diseases
* Postural hypotension, visual problems (which can not be compensated with the correct lens) or vestibular disorders that may affect balance
* Cardiopulmonary diseases that may affect gait
* Orthopedic problems (such as fracture, osteomyelitis, severe osteoporosis), advanced inflammatory arthritis, knee prothesis
* Uncontrolled dyskinesia or motor fluctuation
* Excessive use of alcohol or substance abuse
* Anticoagulant therapy, blood clotting diseases
* Long-term use of corticosteroids
Verticality Perception in Stroke Patients

The long-term goal of this research is to advance our knowledge of how information from the labyrinth is brought to perception and how adaptation to vestibular imbalance influences spatial orientation. In healthy human subjects verticality perception is accurate while upright.The strategy of this research is to quantify changes in verticality perception after unilateral lesions along the central graviceptive pathways and to assess the frequency and pattern of abnormal verticality perception in patients with acute stroke (ischemic or hemorrhagic). Our underlying hypothesis is that screening for erroneous verticality perception by use of a mobile device assessing the subjective visual vertical (SVV) during the acute phase (i.e., within 24-48 hours after symptom onset) reliably identifies those patients with defects. Early detection of deficits in verticality perception may help to initiate balance physiotherapy early.


Eligibility Criteria:
Inclusion Criteria:

1. ages 18-90 years
2. informed consent
3. for group 1: acute (i.e. symptom onset \<3 days ago) lateralized ischemia or hemorrhage as confirmed by clinical examination and / or brain imaging (CT or MRI).
4. absence of exclusion criteria

Exclusion Criteria:

1. history of a peripheral-vestibular deficit
2. disturbed consciousness
3. severe sensory or motor aphasia
4. visual field deficits
5. other neurological or systemic disorder which can cause dementia or cognitive dysfunction
6. intake of antidepressants, sedatives, or neuroleptics
The Distribution of Plasma Drug Concentrations of Beta-lactam Antibiotics in Intensive Care Unit Patients

In this project, intensive care unit (ICU) patients treated with beta-lactam antibiotics are included with the aim to investigate the potential underdosing in this patient group. Four regional ICU-clinics are recruiting consecutive patients (n=120) and samples are taken before the next dose is administered for three consecutive days.


Eligibility Criteria:
Inclusion Criteria:

* Current treatment with beta-lactam antibiotics and admission to the ICU

Exclusion Criteria:

* Pregnancy, age below 18 years